newsfilter
← Latest News
PR Newswire·

Eloxx Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update

Completed underwritten public offering with gross proceeds of $66.0 million and uplisting to the Nasdaq Capital Market, significantly strengthening the Company's balance sheetPhase 2b clinical trial of exaluren in